undamentalytics Newsletter
Sign in

Royalty Pharma plc revenue

Royalty Pharma plc's revenue was $2.38bn in fiscal 2025, up 5.1% on the year before. Since fiscal 2018 ($1.79bn) it has grown at a compound 4.1% a year. Over the last twelve months it was $2.54bn.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1,7951,8142,1222,2892,2372,3552,2642,3782,536
Growth on the year before—+1.1%+17.0%+7.9%−2.3%+5.2%−3.9%+5.1%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Financial Royalty Assets $2.3B 95.1% ▲ 5.2%
Royalty Income Other $117M 4.9% ▲ 2.5%

From Royalty Pharma plc's 10-K filed February 11, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Royalty Pharma plc $2.54bn 10.0% 2.4%
Amneal Pharmaceuticals, Inc. $3.12bn 9.3% 10.5%
Lantheus Holdings, Inc. $1.56bn 2.3% 11.4%
Phibro Animal Health Corp $1.52bn 17.1% 15.8%
Indivior Pharmaceuticals, Inc. $1.37bn 16.3% —
Jazz Pharmaceuticals plc $4.72bn 13.5% 7.5%

Compare with peers

Head to head: AMRX vs RPRXLNTH vs RPRXPAHC vs RPRX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Royalty Pharma plc's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Royalty Pharma plc.